Ortho

Vexcel Data Program Enhances Wide Area Capture Program in U.S. and Europe

Retrieved on: 
Wednesday, September 22, 2021
Aircraft, Ortho, CMOS, GSD, Microsoft MapPoint, CEO, Program, Technology, Industry, Oblique, Surveying, Camera

BOULDER, Colo., Sept. 22, 2021 /PRNewswire/ -- Vexcel Data Program announced today it will enhance its entire Wide Area orthomosaic aerial imagery program to a 15-centimeter (6-inch) ground sample resolution starting in 2022. This program covers the contiguous United States and Western Europe, adding to and refreshing the company's massive aerial imagery and geospatial data library.

Key Points: 
  • BOULDER, Colo., Sept. 22, 2021 /PRNewswire/ -- Vexcel Data Program announced today it will enhance its entire Wide Area orthomosaic aerial imagery program to a 15-centimeter (6-inch) ground sample resolution starting in 2022.
  • The new 15cm Wide Area program has already begun in some regions and will include 100% of the capture area in 2022.
  • In addition to its Wide Area program, Vexcel also collects an Urban Area program capturing ultra-high, 7.5cm-resolution oblique and ortho imagery of major metro areas in Australia, Canada, New Zealand, United Kingdom, United States, and Europe.
  • This makes Vexcel Data Program the only aerial program with both ultra-high resolution urban area and high-resolution wide area data captures in the United States and Europe.

Ortho Clinical Diagnostics Announces Closing of Secondary Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares

Retrieved on: 
Tuesday, September 14, 2021
Form, U.S. Securities and Exchange Commission, Security (finance), UBS, Food, Services and supports for people with disabilities, Efficiency, Health, Nasdaq, BofA Securities, Prospectus, J. P. Morgan, Antibody, Attention, ING, Citigroup, Patient, HIV, Company, Laboratory, Blood, LLC, Hepatitis C, Broadridge Financial Solutions, The Carlyle Group, Food and Drug Administration, Morgan Stanley, IVD, COVID-19, GLOBE, Hospital, Sale, Telephone, Ortho, Exercise, Credit Suisse

As a result of the Closing, the Company is no longer a controlled company within the meaning of the rules of the NASDAQ Global Select Market.

Key Points: 
  • As a result of the Closing, the Company is no longer a controlled company within the meaning of the rules of the NASDAQ Global Select Market.
  • The Company did not sell any ordinary shares in the offering, did not receive any of the proceeds from the offering, and bore the costs associated with the sale of such ordinary shares by the Selling Shareholder, other than underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC and J.P. Morgan acted as the joint lead book-running managers and as representatives of the underwriters for the offering.
  • Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

Ortho Clinical Diagnostics Announces Pricing of Secondary Offering of Ordinary Shares

Retrieved on: 
Friday, September 10, 2021

RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the Company), one of the worlds largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the Companys ordinary shares held by a selling shareholder affiliated with The Carlyle Group (the Selling Shareholder) at a price of $17.50 per ordinary share.

Key Points: 
  • RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the Company), one of the worlds largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the Companys ordinary shares held by a selling shareholder affiliated with The Carlyle Group (the Selling Shareholder) at a price of $17.50 per ordinary share.
  • The Selling Shareholder granted the underwriters a 30-day option to purchase up to 3,300,000 additional ordinary shares of the Company at the public offering price less the underwriting discount.
  • The Company is not selling any ordinary shares in the offering, will not receive any of the proceeds from the offering, and will bear the costs associated with the sale of such ordinary shares by the Selling Shareholder, other than underwriting discounts and commissions.
  • Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

Ortho Clinical Diagnostics Announces Secondary Offering of Ordinary Shares

Retrieved on: 
Tuesday, September 7, 2021

Additionally, the Selling Shareholder expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ordinary shares on the same terms and conditions.

Key Points: 
  • Additionally, the Selling Shareholder expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ordinary shares on the same terms and conditions.
  • The Company is not selling any ordinary shares in the offering, will not receive any of the proceeds from the offering, and will bear the costs associated with the sale of such ordinary shares by the Selling Shareholder, other than underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as the joint book-running managers and as representatives of the underwriters for the offering.
  • Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

Ortho Clinical Diagnostics to Participate in September Investor Conferences

Retrieved on: 
Friday, September 3, 2021
Patient, Food and Drug Administration, Twitter, HIV, COVID-19, Antibody, Efficiency, YouTube, Ortho, Services and supports for people with disabilities, Laboratory, Nasdaq, Hepatitis C, Facebook, Hospital, Blood, LinkedIn, Health, IVD, GLOBE, Food, Medical device, Animal

Management will also host individual meetings with investors at both conferences.

Key Points: 
  • Management will also host individual meetings with investors at both conferences.
  • Ortho Clinical Diagnostics Holdings plc (Ortho) (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.
  • Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.
  • For more information, visit Orthos social media channels: LinkedIn , Twitter , Facebook and YouTube .

The Scotts Miracle-Gro Company Announces Quarterly Dividend Payment

Retrieved on: 
Friday, July 30, 2021
Scotts LawnService, Scotts Miracle-Gro Company, Miracle-Gro, Ohio, Ortho, Scotts, Marysville, Ohio, Dividend, States of the United States, Corporate finance

MARYSVILLE, Ohio, July 30, 2021 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), one of the worlds leading marketers of branded consumer lawn and garden products, announced that its Board of Directors has approved an increase to the Companys quarterly dividend payment to $0.66 per share.

Key Points: 
  • MARYSVILLE, Ohio, July 30, 2021 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), one of the worlds leading marketers of branded consumer lawn and garden products, announced that its Board of Directors has approved an increase to the Companys quarterly dividend payment to $0.66 per share.
  • The fourth quarter dividend is payable on Friday, September 10, 2021, to shareholders of record as of Friday, August 27, 2021.
  • With approximately $4.1 billion in sales, the Company is one of the worlds largest marketers of branded consumer products for lawn and garden care.
  • The Companys Scotts, Miracle-Gro and Ortho brands are market-leading in their categories.

Ortho Clinical Diagnostics to Report Second Quarter 2021 Results on August 4, 2021

Retrieved on: 
Friday, July 23, 2021
Medical tests, Ortho Clinical Diagnostics, Ortho, IVD, In vitro, Medicine, Biology, Natural sciences

RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the worlds largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021.

Key Points: 
  • RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the worlds largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021.
  • Ortho Clinical Diagnostics will hold a conference call the same day at 5:00 pm ET to discuss the results.
  • Interested parties can access the call and accompanying presentation on the Investors portion of the Companys website at https://ir.orthoclinicaldiagnostics.com/ .
  • Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu

Retrieved on: 
Thursday, July 22, 2021
Clinical medicine, Medicine, Branches of biology, Blood tests, Acute-phase proteins, Chemical pathology, Ortho Clinical Diagnostics, Immunologic tests, Ortho, C-reactive protein, Troponin, IVD

IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress, one of the causes of poor outcomes for patients suffering inflammatory diseases.

Key Points: 
  • IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress, one of the causes of poor outcomes for patients suffering inflammatory diseases.
  • Ortho's comprehensive critical care menu also includes tests for hs Troponin, NT-pro BNP, Ferritin, CRP, D-dimer, Lactate, and PCT.
  • Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.
  • Ortho helps its customers enhance clinical outcomes, improve efficiency, overcome staffing challenges and reduce costs.

Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu

Retrieved on: 
Thursday, July 22, 2021
Clinical medicine, Medicine, Branches of biology, Blood tests, Acute-phase proteins, Chemical pathology, Ortho Clinical Diagnostics, Immunologic tests, Ortho, C-reactive protein, Troponin, IVD

IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress, one of the causes of poor outcomes for patients suffering inflammatory diseases.

Key Points: 
  • IL-6 is gaining utility in the evaluation of the most severe forms of respiratory distress, one of the causes of poor outcomes for patients suffering inflammatory diseases.
  • Ortho's comprehensive critical care menu also includes tests for hs Troponin, NT-pro BNP, Ferritin, CRP, D-dimer, Lactate, and PCT.
  • Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.
  • Ortho helps its customers enhance clinical outcomes, improve efficiency, overcome staffing challenges and reduce costs.

Ortho Regenerative Technologies Submits Formal Response to U.S. FDA Clinical Hold

Retrieved on: 
Tuesday, July 20, 2021
Ortho, Tissue engineering

Phase I/II clinical trial preparation activities progressing well with seven (7) leading U.S. clinical sites already pre-qualified

Key Points: 
  • Phase I/II clinical trial preparation activities progressing well with seven (7) leading U.S. clinical sites already pre-qualified
    MONTREAL, July 20, 2021 /PRNewswire/ - Ortho Regenerative Technologies Inc .
  • The FDA requested additional Chemistry, Manufacturing, and Control (CMC) related data and characterization in its June 2021 clinical hold letter.
  • About Ortho Regenerative Technologies Inc.
    Ortho Regenerative Technologies Inc., is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/ortho-regenerative-technologies...
    SOURCE Ortho Regenerative Technologies Inc.